BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ludwicka-Bradley A, Silver RM, Bogatkevich GS. Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum 2011;41:212-22. [PMID: 21168185 DOI: 10.1016/j.semarthrit.2010.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. The molecular virology of coronaviruses. J Biol Chem 2020;295:12910-34. [PMID: 32661197 DOI: 10.1074/jbc.REV120.013930] [Cited by in Crossref: 91] [Cited by in F6Publishing: 60] [Article Influence: 45.5] [Reference Citation Analysis]
2 Singh D, Parihar AK, Patel S, Srivastava S, Diwan P, Singh MR. Scleroderma: An insight into causes, pathogenesis and treatment strategies. Pathophysiology 2019;26:103-14. [PMID: 31130325 DOI: 10.1016/j.pathophys.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Markiewicz M, Richard E, Marks N, Ludwicka-Bradley A. Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases. J Aging Res 2013;2013:734509. [PMID: 24288612 DOI: 10.1155/2013/734509] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
4 Murray LA, Rubinowitz A, Herzog EL. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol 2012;24:656-62. [PMID: 22955020 DOI: 10.1097/BOR.0b013e3283588de4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
5 Huang H, Fava A, Guhr T, Cimbro R, Rosen A, Boin F, Ellis H. A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations. BMC Bioinformatics 2015;16:293. [PMID: 26373409 DOI: 10.1186/s12859-015-0722-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Silver RM, Wilson DA, Akter T, Atanelishvili I, Huggins JT, Kajdasz K, Highland KB, Nietert PJ, Bogatkevich GS. Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease. ACR Open Rheumatol 2019;1:403-11. [PMID: 31777820 DOI: 10.1002/acr2.11049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Landi C, Bargagli E, Bianchi L, Gagliardi A, Carleo A, Bennett D, Perari M, Armini A, Prasse A, Rottoli P, Bini L. Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. Journal of Proteomics 2013;83:60-75. [DOI: 10.1016/j.jprot.2013.03.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
8 Coghlan JG, Schreiber B. An update on the evaluation and management of pulmonary hypertension in scleroderma. Curr Rheumatol Rep 2012;14:1-10. [PMID: 22215445 DOI: 10.1007/s11926-011-0226-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Park GT, Yoon JW, Yoo SB, Song YC, Song P, Kim HK, Han J, Bae SJ, Ha KT, Mishchenko NP, Fedoreyev SA, Stonik VA, Kim MB, Kim JH. Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Mar Drugs 2021;19:237. [PMID: 33922418 DOI: 10.3390/md19050237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Campochiaro C, Allanore Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res Ther 2021;23:155. [PMID: 34074331 DOI: 10.1186/s13075-021-02536-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014;23:183-98. [PMID: 24261610 DOI: 10.1517/13543784.2014.848852] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fuchs PÖ, Calitz C, Pavlović N, Binet F, Solbak SMØ, Danielson UH, Kreuger J, Heindryckx F, Gerwins P. Fibrin fragment E potentiates TGF-β-induced myofibroblast activation and recruitment. Cell Signal 2020;72:109661. [PMID: 32334027 DOI: 10.1016/j.cellsig.2020.109661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Rosas IO, Dellaripa PF, Lederer DJ, Khanna D, Young LR, Martinez FJ. Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11 Suppl 3:S169-77. [PMID: 24754826 DOI: 10.1513/AnnalsATS.201312-429LD] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
14 Schoenfeld SR, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study. Arthritis Care Res (Hoboken) 2016;68:246-53. [PMID: 26212772 DOI: 10.1002/acr.22673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]